Business
Presentation of data at European Conference
Presentation of data at European Conference.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 0536C OptiBiotix Health PLC 17 January 2018 \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nPresentation of research data at European Conference: ProBiota 2018\n \nOptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity,high cholesterol,\ndiabetes and skin care, announces that it has had an abstract accepted for presentation at ProBiota 2018 in Barcelona from 7-9 February 2018. ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiome focused food and pharma industries. The conference is world renowned as a key meeting place for a community of scientists and industry leaders who want to translate science into new products in the growing supplements and ingredients market.\n \nThe abstract reports on the identification and development of a prebiotic which selectively enhances the growth of Lactobacillus rhamnosus GG (\"LGG®\") in the gut. LGG® is the world's best documented probiotic strain and has been described in more than 1000 scientific publications and 300 clinical studies. Christian Hansen acquired the rights and related business for LGG® for a cash consideration of €73 million in September 2016. LGG® is contained within DSM's Culturelle® probiotic range which is the best-selling probiotic supplement brand in the world.\n \nThe abstract will be presented as a poster and oral presentation and demonstrates OptiBiotix's ability to identify and develop targeted prebiotics which can selectively enhance the growth rate and health benefits of specific microbial species, and in doing so enhance the efficacy of probiotic products. This new product concept utilises OptiBiotix's patented approach to the development of optimised synbiotics with the potential to enhance probiotic health benefits, and provide product differentiation in a probiotic market forecast to be worth more than $46.5bn by 2020 (Markets and Markets).\n \nOptiBiotix has filed patents protecting its discoveries of an optimised prebiotic for Lactobacillus rhamnosus, and LGG®, adding to to its extensive existing IP portfolio in this area. \n \nCommenting, Stephen O'Hara, CEO of OptiBiotix said: \"We believe this is the first reported publ...